To the full analysis
Buyback calculator for Pharmanutra
Pharmanutra stock: key metrics
PHN.MIPharmanutra had an operating margin of 23% and a return on invested capital (ROIC) of 33.7% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2015 | 26.9% | 16.3% | 9.8% |
| 2016 | 29.2% | 18.7% | 11.7% |
| 2017 | 32.4% | 23.4% | 16.0% |
| 2018 | 29.4% | 25.5% | 18.3% |
| 2019 | 33.6% | 22.8% | 15.7% |
| 2020 | 36.4% | 22.6% | 24.1% |
| 2021 | 47.2% | 27.4% | 20.2% |
| 2022 | 36.2% | 27.6% | 18.0% |
| 2023 | 48.4% | 23.1% | 12.7% |
| 2024 | 71.3% | 23.6% | 14.3% |
| 2025 | 22.6% | 23.0% | 15.2% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2015 | 62.7% | 30.2% | 16.8% |
| 2016 | 57.9% | 43.9% | 20.3% |
| 2017 | 31.6% | 62.2% | 18.1% |
| 2018 | 35.0% | 69.9% | 20.6% |
| 2019 | 30.0% | 57.4% | 17.3% |
| 2020 | 37.3% | 77.1% | 27.2% |
| 2021 | 30.5% | 75.9% | 19.3% |
| 2022 | 29.5% | 49.9% | 15.0% |
| 2023 | 23.6% | 26.0% | 11.4% |
| 2024 | 26.7% | 29.1% | 14.1% |
| 2025 | 28.0% | 33.7% | 16.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 1 May 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.